Close Menu

BARCELONA – Advanced ovarian cancer patients may benefit from early combination or maintenance treatments that include a PARP inhibitor even if they do not carry germline or somatic mutations in the BRCA1/2 genes, according to data from three Phase III clinical trials presented at the European Society for Medical Oncology Congress this past weekend.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.